A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity.
about
Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infectionCholera toxin: a paradigm of a multifunctional proteinIntranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in miceEffect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in miceIntranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens.Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal deliveryAntipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants.Fusobacterium nucleatum envelope protein FomA is immunogenic and binds to the salivary statherin-derived peptideMucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvantA recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor.Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells.Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissueMucosal immunity and tolerance: relevance to vaccine development.Th17 cytokines and vaccine-induced immunity.Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activationCholera toxin B subunit activates arachidonic acid metabolismZonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens.Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response.Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells.Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin.Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infectionPartially assembled K99 fimbriae are required for protection.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvantGenetically manipulated bacterial toxin as a new generation mucosal adjuvant.A revisit of mucosal IgA immunity and oral tolerance.A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice.Nasal delivery of antigen with the B subunit of Escherichia coli heat-labile enterotoxin augments antigen-specific T-cell clonal expansion and differentiation.Mechanisms for induction of acquired host immunity by neutrophil peptide defensins.Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responsesFunctional modulation of dendritic cells to suppress adaptive immune responses.Oral and nasal sensitization promote distinct immune responses and lung reactivity in a mouse model of peanut allergy.A palindromic CpG-containing phosphodiester oligodeoxynucleotide as a mucosal adjuvant stimulates plasmacytoid dendritic cell-mediated T(H)1 immunity.Oral-nasopharyngeal dendritic cells mediate T cell-independent IgA class switching on B-1 B cells.Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infectionRole of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin
P2860
Q24548763-E1A7BD8F-D6B2-418E-A461-0ACABDEE69BBQ24598726-AB1475F5-1AB0-4B9E-8828-30F2C07B2BC6Q28744391-2C83FBEF-F623-48C1-A621-E419C5B5C643Q28751866-B808838D-DDB4-4E4F-9D39-6716F4688BBCQ33429006-4B4303F3-FA7D-4AB5-8453-6F6A10F06B25Q33584872-5EF65850-0918-488D-A182-B5642C825A36Q33597488-F702CA87-47AC-4F23-9DE8-12C2E04F7B3DQ33675745-E10F951E-E3A3-42F3-9E3C-13976082EA28Q33715999-C8037E32-7755-483F-86BB-902F88AD9451Q33741147-BE823725-28CA-4534-9D11-3177CAEC0846Q33752525-6722BB38-1FE8-485D-B51F-CE50978C2D26Q33768922-F370B0FC-A30B-4324-B3BA-FF9582716F1AQ33769366-D4722C62-E11A-43D7-B5A1-6DCBD78353CDQ33776172-ADD0591D-9EC9-4ED3-99F5-C2CDBC7F6077Q33792227-863EE605-537C-476B-B113-1BBF78530FEDQ33837275-CE2ADECF-3134-4368-A63F-46430C357E44Q33883311-EB9EFB5E-5BB3-470A-8C40-9C1CE9A7EE5BQ34000342-C8F9F425-5304-4F74-9197-F9210F5CEDD3Q34000623-3B7E6AF3-D1DE-463B-8800-1B77A2D7C36CQ34001658-9A902CA2-BC42-48BB-9F2F-19721E3635E8Q34002657-96DC59EA-7EB3-4DDD-A641-101FDE7DB637Q34005585-6A54F70C-0DE3-4364-A127-C254D5F1C500Q34007453-BED19667-F0CD-4150-AEB1-0FC9EB9412FAQ34007563-562F9782-BF33-46FF-BA12-B5D31A26C1C4Q34111838-70AD1FA3-ED59-413C-A605-1B064F22257DQ34128200-6D43E4D9-7005-4BCB-BFE7-ABD575FEA332Q34182385-AE274A95-FB2B-4D5B-9EA0-A70188672353Q34184890-A8A36290-4DC5-4393-B005-0A20B880199EQ34419871-B00724C7-BFDE-4A8D-A353-5A3BC3FD2FBBQ34564412-6626BD53-D782-4830-8FF7-F4CCE25E1E7DQ34675017-F619BD68-DA81-4902-AF65-475681809698Q34761512-535D4A4D-245A-484E-B411-552ECE35A196Q34835899-23063861-9C1F-4E77-BB17-29A4A6986A1BQ34852816-4AC6C0F5-6D96-4EAB-ACB4-FAB6708568DEQ35093120-B2E585B1-0C2B-4070-9D2B-1F890382DA31Q35094515-31D04A0E-FA18-4434-AFCD-91CEC5A7234AQ35106344-06DCEACB-DE21-4B98-9EDE-BD7965882CBCQ35241760-BDFAE76F-AA06-475E-8ACD-F4B0C954FF2AQ35550138-79029D54-A663-469C-96EA-C90277F5A18DQ35559595-FFECE5BA-990E-4C88-8E3E-FB5BC583D0F1
P2860
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
A nontoxic mutant of cholera t ...... for enhanced mucosal immunity.
@ast
A nontoxic mutant of cholera t ...... for enhanced mucosal immunity.
@en
type
label
A nontoxic mutant of cholera t ...... for enhanced mucosal immunity.
@ast
A nontoxic mutant of cholera t ...... for enhanced mucosal immunity.
@en
prefLabel
A nontoxic mutant of cholera t ...... for enhanced mucosal immunity.
@ast
A nontoxic mutant of cholera t ...... for enhanced mucosal immunity.
@en
P2093
P2860
P356
P1476
A nontoxic mutant of cholera t ...... for enhanced mucosal immunity.
@en
P2093
F W Van Ginkel
J R McGhee
K Fujihashi
M Yamamoto
S Yamamoto
P2860
P304
P356
10.1073/PNAS.94.10.5267
P407
P577
1997-05-01T00:00:00Z